RGX-121: Places Clinical Hold on Regenxbio's Gene Therapy
Regenxbio's experimental gene therapy for Hunter Syndrome has been placed on a clinical hold by the FDA after spinal scans found abnormalities in five study participants.
Intelligence analysis by Qwen 2.5 (3B)
Regenxbio's gene therapy for Hunter Syndrome has been placed on a clinical hold by the FDA due to abnormalities found in study participants.
The FDA told a company to stop testing a new medicine for a rare disease. The medicine uses a special virus to fix a problem in the body. The FDA found some problems in the medicine's tests and decided to pause the testing.
Analysis
{"
Clinical Hold Details":"Regenxbio's gene therapy, RGX-121, was placed on a clinical hold by the FDA after spinal scans revealed abnormalities in five study participants who received the treatment for Hunter Syndrome.","
Background on Hunter Syndrome":"Hunter Syndrome is a rare inherited disorder that can cause progressive damage to the brain and other organs and tissues. Current treatment options include Takeda Pharmaceutical's Elaprase and Denali Therapeutics' Avlayah.","
FDA's Concerns":"The FDA's concerns stem from the trial design and supporting evidence for the therapy. The therapy uses a harmless virus known as AAV9 vector to deliver the gene needed to produce the missing enzyme in patients with Hunter syndrome.","
Regulatory Troubles":"This is not the first time Regenxbio has faced regulatory issues. The FDA previously declined to approve RGX-121 over concerns about the trial design and supporting evidence.","
Next Steps":"Regenxbio and its partner NS Pharma will review additional imaging and longer-term follow-up data before deciding the next steps for RGX-121. The company does not expect to resubmit its application for the treatment's approval in the near term."}
Key points
- Regenxbio's gene therapy for Hunter Syndrome has been placed on a clinical hold by the FDA
- The FDA found abnormalities in five study participants who received the treatment
- The therapy uses a harmless virus to deliver the gene needed to produce the missing enzyme in patients with Hunter syndrome
If the company can resolve the issues found in the tests, they may be able to continue testing the medicine and potentially get it approved.
If the company cannot resolve the issues, they may have to stop testing the medicine and may never be able to get it approved.
